Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
03 juin 2024 16h01 HE
|
Eledon Pharmaceuticals, Inc.
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
09 mai 2024 07h30 HE
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
09 mai 2024 07h00 HE
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at ATC 2024
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
07 mai 2024 07h05 HE
|
Eledon Pharmaceuticals, Inc.
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
28 mars 2024 16h01 HE
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
21 mars 2024 10h31 HE
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 févr. 2024 19h01 HE
|
Eledon Pharmaceuticals, Inc.
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 déc. 2023 18h00 HE
|
Eledon Pharmaceuticals, Inc.
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
09 nov. 2023 16h01 HE
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
08 nov. 2023 16h05 HE
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference